Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CERTS presentation on drug risk workshops

Executive Summary

The Centers for Education and Research on Therapeutics will present the research and education agenda resulting from its five therapeutic risk workshops March 6 at the National Press Club in Washington, D.C., at 9 a.m. Workshops to date have covered risk communication, risk assessment and benefit assessment; risk communication & the media will be held on Jan. 7-8 and risk management on Jan. 13-14. The workshops are co-sponsored by CERTs, PhRMA, AHRQ and FDA (1"The Pink Sheet" July 8, p. 21)...

You may also be interested in...



Baycol Withdrawal: Did Public Reaction Cause More Harm Than Drug?

The public reaction to the withdrawal of Bayer's Baycol (cerivastatin) may have caused more harm than the toxicity associated with the drug, Duke Centers for Education & Research on Therapeutics Principal Investigator Robert Califf, MD, told a CERTs workshop in Chapel Hill, N.C., Jan. 8

Drug Risk Assessment Needs IoM Report To Synthesize Research – CERTs

The Institute of Medicine should study the current state of pharmaceutical risk assessment and recommend methodological and research improvements, participants in a Centers for Education & Research on Therapeutics risk assessment workshop suggested

Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.

UsernamePublicRestriction

Register

PS040935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel